12:00 AM
Oct 26, 2015
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg10/23 cls
Biogen Inc. (NASDAQ:BIIB)BairdBrian SkorneyPrice targetNeutral2%$276.99
H.C. WainwrightAndrew FeinPrice targetBuy
JefferiesBrian AbrahamsPrice targetBuy
Skorney lowered his target to $292 from $316. Biogen reported 3Q15 results that beat the Street's estimates; however, growth was driven mostly by inventory and pricing. The company announced plans to cut 11% of its 8,000-employee workforce, which Skorney said "doesn't scream confidence in near-term growth prospects." Biogen also terminated development of Tysabri natalizumab and Tecfidera dimethyl fumarate to treat secondary progressive...

Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >